The oncolytic virotherapy treatment platform for cancer: Unique biological and biosafety points to consider

被引：67

作者：

Vile, R

Ando, D

Kirn, D

机构：

[1] Univ Oxford, Sch Med, Dept Pharmacol, Oxford, England

[2] Mayo Clin, Program Mol Med, Rochester, MN USA

[3] Cell Genesys Corp, Foster City, CA USA

[4] Kirn Oncol Consulting, San Francisco, CA USA

来源：

CANCER GENE THERAPY | 2002年 / 9卷 / 12期

关键词：

oncolytic; virotherapy; experimental therapeutics; cancer;

D O I：

10.1038/sj.cgt.7700548

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The field of replication-selective oncolytic viruses (virotherapy) has exploded over the last 10 years. As with many novel therapeutic approaches, initial overexuberance has been tempered by clinical trial results with first-generation agents. Although a number of significant hurdles to this approach have now been identified, novel solutions have been proposed and improvements are being made at a furious rate. This article seeks to initiate a discussion of these hurdles, approaches to overcome them, and unique safety and regulatory issues to consider.

引用

页码：1062 / 1067

页数：6

共 56 条

[1]

ALEMANY R, 2000, CLIN CANCER RES, V6, P3395

[2]

[Anonymous], P AM SOC CLIN ONCOLO

[3] An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [J].